What is Phronesis AI?
Phronesis AI provides an autonomous AI drug design platform that leverages generative artificial intelligence to create and screen novel small molecules for therapeutic development. The platform enables faster, more cost-effective drug discovery with reduced failure rates through intuitive deep-learning technology.
The company collaborates with leading research institutions and organizations, including Scripps Calibr, Johns Hopkins, and the Gates Foundation, to advance drug candidates from discovery through development. Their expertise spans oncology, central nervous system disorders, metabolic diseases, and infectious diseases, supported by a team with experience in pharmaceutical leadership and AI-driven strategies.
Features
- Generative AI Design: Creates novel small molecules using artificial intelligence
- Deep-Learning Platform: Intuitive system for autonomous drug design and screening
- Collaborative Network: Partners with top research institutions and organizations
- Expert Team: Experience in drug development with 35 approved therapies and numerous publications
Use Cases
- Accelerating small molecule drug discovery for pharmaceutical companies
- Screening novel therapeutic compounds for research institutions
- Reducing costs and failures in drug development projects
- Advancing treatments for oncology, CNS disorders, metabolic diseases, and infectious diseases
